Evidence map›Paper›PMID 33774512›Full record

ArticlePublic health2021

Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection.

E Murillo-Zamora, O Mendoza-Cano, I Delgado-Enciso, C M Hernandez-Suarez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. COVID-19 vaccines provide better protection against related pneumonia than previous symptomatic infection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

E Murillo-ZamoraDepartamento de Epidemiología, Unidad de Medicina Familiar No. 19, Instituto Mexicano del Seguro Social, Av. Javier Mina 301, Col. Centro, C.P. 28000, Colima, Colima, Mexico; Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, Mexico. Electronic address: efren.murilloza@imss.gob.mx.
O Mendoza-CanoFacultad de Ingeniería Civil, Universidad de Colima, Km. 9 Carretera Colima-Coquimatlán, Coquimatlán, C.P. 28400, Colima, Mexico. Electronic address: oliver@ucol.mx.
I Delgado-EncisoFacultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, Mexico; Instituto Estatal de Cancerología de los Servicios de Salud del Estado de Colima, Av. Liceo de Varones 401, Col. La Esperanza, C.P 28085, Colima, Colima, Mexico. Electronic address: ivan_delgado_enciso@ucol.mx.
C M Hernandez-SuarezFacultad de Ciencias, Universidad de Colima, Bernal Díaz del Castillo 340, Col. Villas San Sebastián, C.P. 28045, Mexico. Electronic address: carlosmh@mac.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the study was to evaluate factors predicting severe symptomatic laboratory-confirmed (via Reverse transcription polymerase chain reaction, RT-PCR polymerase chain reaction) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. STUDY

designThis is a nationwide retrospective cohort study that was conducted in Mexico.

methodsData from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RRs) and 95% confidence intervals (CIs) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-CoV-2 infection.

resultsThe risk of severe disease was 14.7%, and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, P < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-CoV-2 reinfection were increasing age (RR

conclusionsTo the best of our knowledge, this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-CoV-2 reinfection, and factors associated with illness severity were characterized. Our results may contribute to the current knowledge of SARS-CoV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.

Indexed as

Severity of Illness IndexAdultAgedComorbidityCOVID-19COVID-19 Nucleic Acid TestingFemaleHospitalizationHumansLaboratoriesMaleMexicoMiddle AgedReinfectionRetrospective StudiesRisk FactorsCohort studiesCOVID-19PrognosisReverse transcription polymerase chain reactionSevere acute respiratory syndrome coronavirus 2

Identifiers

PMID33774512
PMCPMC7879028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.